Stem Cell Clinic

Luca Biavati, MD, on Bone Marrow T-Cells for Adoptive Cell Therapy – Cancer Network

Luca Biavati, MD, from Johns Hopkins Medicine, discussed bone marrow T-cells and bone marrow infiltrating lymphocytes as a source for adoptive cell therapy at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).

Transcript:

So, the conference is about cancer immunotherapy. And what makes me excited about it is, I study bone marrow T-cells and bone marrow infiltrating lymphocytes as a source for adoptive cell therapy. So, the whole conference is about the use of either monoclonal antibodies or vaccines or adoptive cell therapy to at least improve treatment of cancer.

Ive seen several posters and presentations about how to study the tumor micro-environment and T-cells, and also several ways on how to improve adoptive cell therapy and immunotherapy in several different solid tumors and hematological cancers.

And there have been several improvements on the applicability of these techniques. Theyre still a lot expansive, but I see that maybe theyre going to be more available and definitely more efficient and effective in the foreseeable future.

Well in 5 years probably like well have a whole new set of problems we are not actually seeing right now, as it happened like 5 years ago when we were thinking about now. So yeah, probably like well have new issues with cancer therapies that now we dont see because were not close enough to see that kind of problems yet. Probably like better progression-free survival, better treatments, and then obviously new problems.

See the original post:
Luca Biavati, MD, on Bone Marrow T-Cells for Adoptive Cell Therapy - Cancer Network

Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation – BioSpace

Being the first company to test a CAR-Treg candidate in humans is an important milestone for Sangamo and this exciting new frontier of cellular therapy. We believe that the TX200 program will be invaluable in expanding our understanding of the safety and mechanism of action of CAR-Treg cells and their relevance in the clinic, said Adrian Woolfson, BM, BCh, PhD, Head of Research and Development at Sangamo. This innovative and personalized cellular therapy approach for HLA-A2 mismatched kidney transplantation is designed to help regulate the bodys immune system specifically and locally to promote acceptance of an immunologically mismatched donor organ. Beyond transplantation, we plan to explore the potential of CAR-Tregs in a range of autoimmune and inflammatory diseases.

TX200 is an autologous (cells collected from the patient) HLA-A2-targeted CAR-Treg cell therapy. The patients regulatory T cells (Tregs), a type of white blood cell which plays a key role in regulating the immune response and inflammation, are collected and genetically engineered with a Chimeric Antigen Receptor (CAR) designed to bind to HLA-A2. HLA-A2 is a protein belonging to the human leukocyte antigen (HLA) system. Donor/recipient mismatch in HLA molecules is a primary contributor to organ transplant incompatibility and may ultimately lead to immune-mediated rejection of the transplanted organ. The recipients immune system can recognize this HLA-A2 mismatch and may attack the new kidney carrying the HLA-A2 protein, potentially leading to graft rejection.

TX200 HLA-A2 CAR-Treg cells are designed to accumulate and localize within the new kidney where the HLAA2 protein is present, thereby utilizing the ability of Tregs to suppress immune responses against the transplanted kidney. This approach aims to help the recipients immune system accept the new kidney and induce immunological tolerance, potentially allowing tapering and eventual elimination of accompanying standard-of-care immune suppressive treatments.

Kidney transplantation is the treatment of choice for patients with ESRD who must otherwise remain on long-term dialysis. To prevent graft rejection, transplanted patients are treated with lifelong immune suppressive therapy, which impacts the bodys immune system broadly and is associated with multiple side effects, including an increased risk of infectious complications, cancer, and other drug-related toxicities.

TX200, which has been developed in collaboration with Professor Megan Levings of the University of British Columbia1, entered Sangamos pipeline in 2018 as part of the acquisition of TxCell. Beyond kidney transplantation, Sangamo intends to use its zinc finger nuclease (ZFN) gene editing technology to develop next-generation autologous and allogeneic CAR-Treg cell therapies for use in treating autoimmune and inflammatory diseases.

About the STEADFAST study

The STEADFAST study is a multicenter, open-label, single ascending dose, dose-ranging Phase 1/2 study. Sangamo plans to run this study in five different countries in Europe: United Kingdom, France, Netherlands, Germany, and Belgium.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit http://www.sangamo.com.

Forward Looking Statements

This press release contains forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, statements regarding the potential benefits of cell therapy, including but not limited to Treg therapy, the Company's ability to develop and commercialize product candidates to address genetic diseases with the Company's proprietary technologies and the timing of commencement or next stages of such programs and the anticipated benefits therefrom. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the outcomes of clinical trials, the uncertain regulatory approval process, uncertainties related to the execution of clinical trials and uncertainties that research outcomes will support clinical programs. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on March 1, 2019 and Sangamo's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 that it filed on November 6, 2019. TX200 is an investigational product and has not been determined to be safe or efficacious by regulatory authorities. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005346/en/

See original here:
Sangamo Announces UK Authorization of a Phase 1/2 Clinical Trial Evaluating the CAR-Treg Cell Therapy TX200 for Kidney Transplantation - BioSpace

Kiadis sheds half its staff as lead cell therapy bombs – – pharmaphorum

Dutch biotech Kiadis Pharma has abandoned its lead cell therapy and axed half its workforce after a failed phase 3 trial forced a complete rethink of its strategy.

The decision to drop ATIR101 for graft-versus-host disease (GVHD) a complication of transplants comes after an interim analysis of data from its phase 3 trial which suggested the T-cell immunotherapy was unlikely to show an improvement over cyclophosphamide, a standard therapy for GVHD.

Amsterdam-based Kiadis says that survival was better in the cyclophosphamide group than had been expected when the trial was designed. Also, there were fewer than expected cases of severe GVHD in the control arm so a much larger study would be required to show an effect of ATIR01.

Despite spending several years developing ATIR01, Kiadis has decided to cut its losses and refocus on its natural killer (NK) cell therapies, which are at an earlier stage of clinical development.

The announcement caught investors by surprise, despite earlier warnings by the biotech that all was not well with the programme and chances of an approval in 2020 were looking increasingly shaky.

Those concerns proved well-founded after the EMA rejected its regulatory filing for the therapy last month, having previously also turned it down in 2017. The phase 3 trial was designed to put ATIR-1 back on track, however, and in the meantime Kiadis had been building production capacity as it geared up for a possible commercial launch.

Shares in the biotech lost a third of their value after the announcement yesterday, and continued to slide today as investors who backed the company with a 28 million private placement in May to help fund the phase 3 programme digested the news that Kiadis remains several years away from having a therapy on the market.

Shareholders are also having to adjust to the pivot towards the NK cell therapy pipeline, which includes therapies based on cells harvested from patients as well as off-the-shelf treatments.

Staff involved in the commercial scale-up of ATIR01 are bearing the brunt of the layoffs as Kiadis cuts its costs and redirects its cash reserves at around 47 million (around $52 million) as of the end of the third quarter to the NK programmes.

Its most advanced candidate now is K-NK002, that aims to reduce blood cancer relapse after bone marrow transplants that will once again be compared with cyclophosphamide standard therapy. A phase 1/2 trial is due to start next year.

Also heading for a phase 1/2 trial in 2020 is K-NK003 for patients with relapse and refractory acute myeloid leukaemia, according to the biotech.

Read more from the original source:
Kiadis sheds half its staff as lead cell therapy bombs - - pharmaphorum

The Conference Forum Announces the Launch of Cell & Gene Therapy Day in NYC – PR Web

We are witnessing significant innovation in cell and gene therapies, and we are at a turning point of advancing these technologies for solid tumors.

NEW YORK (PRWEB) November 19, 2019

The inaugural Cell & Gene Therapy Day takes place February 27, 2020 at the Crowne Plaza Times Square in New York City. The one-day event will be chaired by Dr Aiman Shalabi, VP R&D, Cell and Gene Therapies for GSK, with a diverse group of leaders in the space.

We are witnessing significant innovation in cell and gene therapies, and we are at a turning point of advancing these technologies for solid tumors, said Dr Shalabi. This conference will engage global leaders on a series of scientific, investment landscape, regulatory and manufacturing topics with the ambition of accelerating these treatments to patients with solid cancers.

Cell & Gene Therapy Day will focus primarily on the promising data and progress for solid tumors. IO and cell therapy expert Dr Arie Belldegrun, Allogene, is the opening keynote and will kick off the day by addressing advancements in CAR-T cell therapy.

Immunotherapy expert, Dr Crystal Mackall, Director of the Stanford Center for Cancer Cell Therapy at Stanford University School of Medicine, will deliver a cornerstone presentation on new scientific frontiers in cell therapies for solid tumors. Dr Mackall has been a leader in treating hematologic tumors, with extensive work using CAR to target CD19 and CD22 in childhood leukemia.

The day will touch upon several different areas of cell and gene therapy. Dr Peter Marks, Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration, will lead a panel on the evolution of regulatory policy for cell and gene therapy.

IO360 veteran Dr Ramy Ibrahim, Parker Institute for Cancer Immunotherapy, will address master protocols in cell and gene therapy, and his companys own innovations in the field. Dr Ibrahim will also lead a discussion on the latest in collaborative development paradigms for cell therapies with Dr Elad Sharon, National Cancer Institute, and Dr Mitch Finer, ElevateBio.

Leaders from Loncor Investments, Cancer Research Institute, IQVIA and the Alliance for Regenerative Medicine will trace through the landscape and evolution of the cell and gene therapy marketplace.

One portion of the day will focus on pivotal developments in solid tumor treatment. The National Institutes of Healths Dr Stephanie Goff will address tumor-infiltrating lymphocytes as a way of treating cancer. Dr Maria Fardis, Iovance, will speak on TILs as a way targeting individual tumor mutations. Dr Shalabi will return for an update on NY-ESO-1. Dr John Connolly, Tessa Therapeutics, will highlight the prognostic values of antiviral responses and using virus-specific T cells as a solid tumor immunotherapy platform. The day will conclude with debates on combinations with checkpoints, and bedside versus centralized manufacturing.

About Cell & Gene Therapy Day: Cell & Gene Therapy Day convenes stakeholders spanning the science and business communities to report on the latest cell and gene therapy progress to fight a wider range of cancers beyond hematologic malignancies. Cell & Gene Therapy Day is available an independent one-day program with a luncheon and networking reception, or attendees can register for the three day IO360 program, which includes the Cell & Gene Therapy Day. For more information on IO360, please click here.

About the Conference Forum:The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. They are committed to creating the best content, exchange of ideas and solutions among peers, as well as providing high-quality networking.

Share article on social media or email:

See original here:
The Conference Forum Announces the Launch of Cell & Gene Therapy Day in NYC - PR Web

BioCardia Reports 2019 Third Quarter Financial Results and Business Highlights – GlobeNewswire

SAN CARLOS, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- BioCardia, Inc.[Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the third quarter 2019 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2019 with the Securities and Exchange Commission.

Update on Ongoing CardiAMP Autologous Cell Therapy Pivotal Heart Failure Trial:The company recently received FDA approval for an IDE supplement for the Phase III pivotal CardiAMP Heart Failure Trial of its lead therapeutic candidate. This will enable patients in the control group to cross over to CardiAMP treatment once their follow-up for the CardiAMP Trial has been completed. The IDE supplement also enables BioCardia to cover all out-of-pocket insurance co-pays for patients with Medicare coverage, so their participation in the trial will now be free. These two areas were previously barriers to participation for patients, who were eager to receive the therapy and less interested in being in the control arm, and were also responsible for their own co-pays. The company expects these changes, coupled with site-specific action plans, to further accelerate trial enrollment, which currently stands at 58 patients enrolled to date at 24 world class U.S. centers.

Third Quarter 2019 Business Highlights:

Third Quarter 2019Financial Results:

Achievements around our investigational CardiAMP cell therapy were the highlights of the last quarter, with a positive DSMB review, FDA approval of our IDE supplement, and a new European patent recognizing the innovation inherent in our pre-treatment assay designed to optimize patient outcomes and lower costs, said BioCardia CEO Peter Altman, PhD. At the same time, we made great progress with our other innovations: the first commercial use of the new AVANCE steerable introducer sheath in September, which can leverage the growing market for transseptal procedures, and extension of our AstraZeneca relationship, which enables our Helix delivery system to be used with new therapies being developed outside of the company.

Anticipated Upcoming Milestones:

About BioCardiaBioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP and CardiALLO cell therapies are the Companys biotherapeutic product candidates in clinical development. The Company's current products include the Helix transendocardial delivery system, the Morph steerable guide and sheath catheter portfolio, and the new AVANCE steerable introducer family. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.

Forward Looking Statements This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to the enrollment of our clinical trials, the availability of data from our clinical trials, filings with the FDA, FDA product clearances, the efficacy and safety of our products and therapies, statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardias business and product development plans and overall market conditions. We may find it difficult to enroll patients in our clinical trials due to many factors, some of which are outside of our control. Slower than targeted enrollment could delay completion of our clinical trials and delay or prevent development of our therapeutic candidates. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.

We may use terms such as believes, estimates, anticipates, expects, plans, intends, may, could, might, will, should, approximately or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardias Form 10-Q filed with the Securities and Exchange Commission on August 9, 2019, including under the caption titled Risk Factors. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Media Contact: Michelle McAdam, Chronic Communications, Inc.Email:michelle@chronic-comm.comPhone: 310-902-1274

Investor Contact: David McClung, Chief Financial OfficerEmail:investors@BioCardia.comPhone: 650-226-0120

BIOCARDIA, INC.Condensed Statements of Operations

(Unaudited In thousands, except share and per share amounts)

Here is the original post:
BioCardia Reports 2019 Third Quarter Financial Results and Business Highlights - GlobeNewswire

The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 2018-2024 – P&T Community

NEW YORK, Nov. 18, 2019 /PRNewswire/ --

The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 20182024.

Read the full report: https://www.reportlinker.com/p05827567/?utm_source=PRN

The major drivers contributing to the growth of the global cell and gene therapy market are the growing incidence of several chronic and terminal diseases, including cancer, the launch of new products, the increasing availability in clinical evidences of these products in terms of safety and efficacy, the rapid adoption of CAR T-cell therapy, favorable regulatory support in the development of these treatment, and improved manufacturing expertise in these products.

The following factors are likely to contribute to the growth of the cell and gene therapy market during the forecast period: Increased Pool of Patient Population with Several Ailments Favorable Regulatory Support and Increasing Special Designations for Cell and Gene Therapy Products Growing Demand for CAR T-cell Therapy Products Increasing Strategic Acquisition Activities

The study considers the present scenario of the cell and gene therapy market and its market dynamics for the period 2018?2024. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply aspects of the market. The report profiles and examines leading companies and other prominent companies operating in the market.

Cell and Gene Therapy Market: Segmentation

This research report includes detailed market segmentation by product, application, end-user, and geography. The global cell therapy market is growing at a steady rate, and this trend is expected to continue during the forecast period due to the increased patient base with a wide range of diseases/ailments. The segment is likely to witness upward growth on account of expanded expertise in the manufacturing of stem cell-based products.

The gene therapy segment is expected to witness faster growth as the penetration of these products is increasing at a significant rate, especially in developed economies. The market is expected to grow during the forecast period due to the increased patient base for the existing gene remedy products, expected the launch of other gene therapy-based products for several indications, and expanded indication approvals for existing commercially available products.

The oncology segment accounts for the highest share of the global market. The growth of the oncology segment is increasing at a fast rate on account of the growing prevalence of several types of cancers. Currently, the available products not only modify the disease but also improve the quality of the patient's life, thereby decreasing the mortality rate. The market in the dermatology segment is increasing at a steady rate. This segment owns its growth to the increasing incidence and prevalence rate of several types of wounds, which are difficult to treat under normal conditions and the launch of innovative products. The dermatology segment is likely to showcase growth due to the high product availability of wound care products in the market.Hospitals are the leading end-user segment. The segment is growing mainly due to the increasing incidence/prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, and chronic wound on account of diabetes feet, pressure ulcers, and other injuries.

Market Segmentation by Products Cell Therapy Gene TherapyMarket Segmentation by Distribution Channel Type Oncology Dermatology Musculoskeletal OthersMarket Segmentation by End-users Hospitals Wound Care Centers Cancer Care Centers Ambulatory Surgical Centers Others

Geographical Insights

The US market dominates the cell and gene therapy market in North America due to the high prevalence of chronic diseases and other conditions, which require these treatment methods. There is also comparably high utilization and wide accessibility of these therapies. The oncology segment is likely to witness significant growth in North America.The market in Europe is expected to witness upward growth in the near future on account of the growing prevalence of chronic diseases and rising elderly population. In Europe, cell and gene therapy products are considered to be part of the Advanced Therapy Medicinal Products (ATMPs), which are commonly known as regenerative medicine globally.

Market Segmentation by Geography North Americao USo Canada APACo Japano Chinao South Koreao Australia Europeo Germanyo Franceo UKo Spaino Italy Latin Americao Brazilo Mexico MEAo Turkeyo Saudi Arabiao UAE

Key Vendor AnalysisThe global market is characterized by the presence of a few global, large-scale companies and several small to medium-scale companies offering one or two cell and gene therapy products. Global players are majorly offering innovative products with the potential of disease-modifying characteristics that are generating significant revenues, especially in Europe and US regions. Most innovative and breakthrough products are approved in the European countries and the US. Vendors are targeting mostly developed economies such as the US, Germany, France, the UK, Spain, and Japan as the uptake of these products is higher in these countries than low and middle-income countries. However, the market in these regions is at the nascent stage.

Key Vendors Gilead Sciences Spark Therapeutics Novartis AG Organogenesis Amgen Osiris Therapeutics Dendreon Vericel

Other Prominent Vendors Anterogen Tego Sciences Japan Tissue Engineering JCR Pharmaceuticals Medipost MolMed AVITA Medical CollPlant Corestem Biosolution Stempeutics Research Orchard Therapeutics Takeda Pharmaceutical Company CHIESI Farmaceutici CO.DON AnGes GC Pharma JW CreaGene APAC Biotech Nipro Corp. Terumo Orthocell bluebird bio

Key Market InsightsThe report provides the following insights into the market for the forecast period 20192024. Offers sizing and growth prospects of the market for the forecast period 20192024. Provides comprehensive insights on the latest industry trends, forecast, and growth drivers in the market. Includes a detailed analysis of growth drivers, challenges, and investment opportunities. Delivers a complete overview of segments and the regional outlook of the market. Offers an exhaustive summary of the vendor landscape, competitive analysis, and key strategies to gain a competitive advantage.

Read the full report: https://www.reportlinker.com/p05827567/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-cell-and-gene-therapy-market-is-growing-at-a-cagr-of-over-24-during-the-forecast-period-20182024-300959839.html

SOURCE Reportlinker

Follow this link:
The global cell and gene therapy market is growing at a CAGR of over 24% during the forecast period 2018-2024 - P&T Community

The Cell and Gene Therapy Market to Reach Revenues of Over $6.6 billion by 2024 – Market Research by Arizton – PRNewswire

CHICAGO, Nov. 13, 2019 /PRNewswire/ -- According to Arizton's recent research report, Cell and Gene Therapy Market - Global Outlook and Forecast 2019-2024 is expected to grow at a CAGR of more than 24% during the forecast period.

Key Highlights Offered in the Report:

Key Offerings:

Get your free sample today! https://www.arizton.com/market-reports/cell-and-gene-therapy-market

Cell and Gene Therapy Market Segmentation

Market Segmentation by Products

Market Segmentation by Distribution Channel Type

Market Segmentation by End-users

Cell and Gene Therapy Market Dynamics

CAR T-cell therapy has gained significant traction in recent years. It is the single most rapidly growing type of product in the market that generates revenue at a phenomenal rate. At present, it is the fastest advancing technology in cancer treatment and has the capability to replace many existing therapies. CAR T-cell therapy addresses current challenges in cancer care through superior efficacy, safety, and delivery mechanisms. CAR T-cell therapy has brought itself into focus due to the personalized nature of this therapy and the utilization of advanced genetic engineering technology. The wide acceptance and use of CAR T-cell therapy is fueling the growth of the global cell and gene therapy market.

Key Drivers and Trends fueling Market Growth:

Cell and Gene Therapy MarketGeography

The US dominates the cell and gene therapy market in North America due to the high prevalence of chronic diseases and other conditions. There is also comparably high utilization and wide accessibility of these therapies. In Europe, cell and gene therapy products are considered to be part of the Advanced Therapy Medicinal Products (ATMPs), which are commonly known as regenerative medicine globally. The major factors leading to the growth in APAC region are the growing prevalence of cancers, osteoarthritis, burns, and other chronic wounds, the introduction of advanced products in Japan, advanced R&D activities in countries such as South Korea, India.

Get your free sample today! https://www.arizton.com/market-reports/cell-and-gene-therapy-market

Market Segmentation by Geography

Major Vendors

Other vendors include - Anterogen, Tego Sciences, Japan Tissue Engineering, JCR Pharmaceuticals, Medipost, MolMed, AVITA Medical, CollPlant, Corestem, Biosolution, Stempeutics Research, Orchard Therapeutics, Takeda Pharmaceutical Company, CHIESI Farmaceutici, CO.DON, AnGes, GC Pharma, JW CreaGene, APAC Biotech, Nipro Corp., Terumo, Orthocell, and bluebird bio.

Explore our healthcare & lifesciencesto know more about the industry.

Read some of the top-selling reports:

About Arizton:

Arizton Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on industries such as consumer goods & retail technology, automotive and mobility, smart tech, healthcare, and life sciences, industrial machinery, chemicals and materials, IT and media, logistics and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Mail: enquiry@arizton.comCall: +1-312-235-2040 +1-302-469-0707

SOURCE Arizton Advisory & Intelligence

Original post:
The Cell and Gene Therapy Market to Reach Revenues of Over $6.6 billion by 2024 - Market Research by Arizton - PRNewswire

The Cell and Advanced Therapies Supply Chain Management Market is Anticipated to Grow at an Annualized Rate of 11% till 2030, Claims Roots Analysis -…

Over time, biopharmaceutical companies have realized the importance of integrating advanced software into the cell and advanced therapies supply chain. Such upgrades have demonstrated the ability to offer both time and cost saving

LONDON, Nov. 19, 2019 /PRNewswire/ -- Roots Analysishas announced the addition of the "Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions (Cell Orchestration Platforms, Enterprise Manufacturing Systems, Inventory Management Systems, Laboratory Information Management Systems, Logistics Management Systems, Patient Management Systems, Quality Management Systems, Tracking & Tracing Systems, and Other Software), 2019-2030" report to its list of offerings.

The cell and advanced therapies supply chain is complex, with several legacy challenges, such as those related to patient scheduling, resource planning, inventory management, and deliverable tracking. A number of innovative, software-enabled systems are available / under development to mitigate the aforementioned concerns and simplify the management of biopharmaceutical supply chains.

To order this 420+ page report, which features 150+ figures and 350+ tables, please visit this link

Key Market Insights

Over 160 software-enabled supply chain management systems are currently available

Of these, more than 25% are inventory management systems (IMS), which are primarily used for tracking inventory, orders, sales and deliveries. Examples include (in alphabetical order) ATiM Software, Benchling Inventory, CryoTrackIMS, Cryotrax, CTM-STAR, Lynx Mobile, Mosaic FreezerManagement, and Stafa Apheresis.

~80% of marketed solutions are used in collection centers and sample storage warehousesFurther, about 49% of such systems are being implemented to streamline manufacturing operations of cell and advanced therapies.

Cloud-based deployment is gradually gaining popularity

Stakeholders claim that such deployment methods can be rapidly provisioned with minimal management effort (often over the internet), allowing for faster implementation. At present, about 47% of the software systems are being deployed via cloud; examples include (in alphabetical order) Chronicle automation software, Cryoportal, evo.is, PAS-X MES, STARLIMS, tempmate-CLOUD, and TrakCel.

Around 57% of the stakeholders in this industry are based in the US

This can be attributed to the increasing interest in cell and advanced therapies in this region, making North America the current hub of innovation in this field. It is followed by players in the EU (35%) and Asia Pacific (8%).

2,600+ tweets focused on the increasing interest and ongoing efforts of industry stakeholders

Social media analysis revealed that many biopharmaceutical developers are adopting software-enabled supply chain management solutions with increasing enthusiasm. In fact, many of the tweets were related to the ability of such systems to resolve the challenges associated with large volumes of supply chain data.

Over 10 supply chain orchestration solutions are currently available in the market

These solutions have demonstrated the ability to efficiently integrate core software systems, in order to offer needle-to-needle traceability within complex supply chains.

~USD 650 million has been invested by both private and public investors, since 2014

Of this, close to USD 300 million was raised through venture capital funding rounds, representing 47% of the total capital raised. Further, there were five instances of IPOs / secondary offerings, accounting for USD 280 million in raised capital.

Partnership activity has increased at an annualized rate of 14%

In fact, around 55% of the reported deals were established post 2016; the maximum partnership activity was observed in 2018. Majority of these agreements (75+) were observed to be focused on platform integration or the establishment of service alliances.

North America and Europe are anticipated to capture over 85% market share by 2030

In addition to North America and Europe, the market in China / broader Asia Pacific region is also anticipated to grow at a relatively faster rate.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered

The financial opportunity within the cell and advanced therapies supply chain management market has been analyzed across the following segments:

The report features inputs fromeminent industry stakeholders, according to whom software-enabled supply chain management systems have the potential to eliminating risks, and reducing time and capital investment in the cell and advanced therapy development process. The report includes detailed transcripts of discussions held with the following experts:

The research includes elaborate profiles of key stakeholders (listed below), featuring a brief company overview, its financial information (if available), and a detailed description of its platform(s), recent developments and an informed future outlook.

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/cell-therapies-supply-chain/260.htmlor email sales@rootsanalysis.com

You may also be interested in the following titles:

1. Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market (3rd Edition), 2019-2030 (Focus on AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA and Other Vectors)

2. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 2030

3. Stem Cell Therapy Contract Manufacturing Market, 2019-2030

4. Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030

5. Cell and Gene Therapy CROs Market, 2018-2030

Contact:

Gaurav Chaudhary+1(415)-800-3415Gaurav.Chaudhary@rootsanalysis.com

Excerpt from:
The Cell and Advanced Therapies Supply Chain Management Market is Anticipated to Grow at an Annualized Rate of 11% till 2030, Claims Roots Analysis -...

Cell Therapy Market 2019 In-depth Analysis with Inputs from Key Industry Participants – Research Writeups

Cell therapy (also called cellular therapy or cytotherapy) is therapy in which cellular material is injected into a patient; this generally means intact, living cells. For example, T cells capable of fighting cancer cells via cell-mediated immunity may be injected in the course of immunotherapy.

This report on the globalCell Therapy Marketis a detailed research study that helps provides answers and related questions with respect to the emerging trends and growth opportunities in this particular industry. It also highlights each of the prominent factors related to the growth of the market are; growing GDP, demographics, increasing purchasing power, increasing demand, government incentives, government policies, regulatory policies, product standards.

Click the link to get a Sample Copy of the Report before purchase:

https://www.marketinsightsreports.com/reports/07161360927/global-cell-therapy-market-size-status-and-forecast-2019-2025/inquiry?Mode=BRG10

Top Companiesin the Global Cell Therapy Market (Sales, Price, Revenue, value, volume, market share)-:Dendreon, Mesoblast, Vericel, Novartis AG, GlaxoSmithKline plc, MEDIPOST, Osiris, PHARMICELL, NuVasive, Inc., JCR Pharmaceuticals Co., Ltd, ANTEROGEN.CO.,LTD., Cynata, CELLECTIS, BioNTech IMFS, EUFETS GmbH, Cognate, Pluristem, Grupo Praxis, Genzyme Corporation, Advanced Tissue,and others.

Market Segment by Type

AutologousAllogeneic

Market Segment by Application

Hospitals and clinicsASCsRegenerative medicine centers

Cell therapy products, which are derived from stem cells, tissues, and organs grown in laboratories, are injected into patients. The growing number of clinical trials, government and private funding, and increasing number of partnerships between companies are driving the growth of the global cell therapy market. Cell therapy products that are available in the market are based on autologous and allogenic cells. The demand of cell therapy treatment is increasing. This is because cell therapy products can be used for personalized treatment.

Market Segment by Regions, regional analysis covers:

North America (the United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, and Italy)

Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

South America (Brazil, Argentina, Colombia, etc.)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

You will be able to rely on the comprehensive country coverage, including:

(Special Offer: Get Up-to 20% discount on this report)

Inquire for Discount:

https://www.marketinsightsreports.com/reports/07161360927/global-cell-therapy-market-size-status-and-forecast-2019-2025/discount?mode=BRG10

All of the segments studied in the research study are analyzed on the market share, revenue, and other important factors. Our research study shows how different segments are contributing to the growth of the global Cell Therapy market. It also provides information on key trends related to the segments included in the report. This helps market players to concentrate on high-growth areas of the global Cell Therapy market. The research study also offers separate analysis on the segments on the basis of absolute dollar opportunity.

What is present in the report?

Detailed analysis of data center for specific country

Current opportunity and future potential identification

Most exhaustive and updated report

Helps to identify the current trends, challenges and market drivers

Covers value chain evolution and changing distribution dynamics

Know what your competitors are doing in the market

Order a copy of Global Cell Therapy Market Report 2019 @

https://www.marketinsightsreports.com/report/purchase/07161360927?mode=su?Mode=BRG10

Customization of the Report:This report can be customized as per your needs for additional data up to 3 companies or 3 countries or nearly 40 analyst hours.

Please connect with our sales team(sales@marketinsightsreports.com).

About Us:

MarketInsightsReportsprovides syndicated market research on industry verticals including Healthcare, Information, and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.MarketInsightsReportsprovides global and Chinese and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Sales)

Phone: + 1704 266 3234 | +91-750-707-8687

sales@marketinsightsreports.com | irfan@marketinsightsreports.com

Original post:
Cell Therapy Market 2019 In-depth Analysis with Inputs from Key Industry Participants - Research Writeups

Global CAR T-Cell Therapy for Multiple Myeloma Market 2019 Company Business Overview – Juno Therapeutics, Kite Pharma, Novartis, Collectis – Hitz…

Fior Markets has offered a new market study research namely Global CAR T-Cell Therapy for Multiple Myeloma Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2024, providing an overall analysis of the CAR T-Cell Therapy for Multiple Myeloma market. The goal of analyzing the complete market was achieved with the help of the previously collected chronological data, the exhaustive qualitative insights, and the statistical data of the market. This study is an effort to provide valuable intelligence for globalbusinesses that are taking effort to obtain dominance over the industry and maximum revenue outcome. It investigates substantial market occurrences from 2014 to 2018 and offers authentic and reliable predictions of up to 2024 that help market players make informed business decisions accordingly.

The report revolves around a historic and present market status to obtain valuable forecast analysis based on market size, share, trends, sales volume, revenue, and growth rate. Various statistics included in the report are made using technical data and industry figures sourced from the most reputable databases. Other aspects of the report that are beneficial to reader include investment feasibility analysis, recommendations for growth, investment return analysis, trends analysis, opportunity analysis, and SWOT analyses of competing companies.

DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report-detail/321825/request-sample

Market share of global CAR T-Cell Therapy for Multiple Myeloma industry is dominated by companies likeJuno Therapeutics, Kite Pharma, Novartis, Collectis,

On the basis of product, this report displays the production, revenue, price, market share, and growth rate of each type, primarily split into Monotherapy, Combination Therapy

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share, and growth rate for each application, including Multiple Myeloma, Refractory or Relapsed Multiple Myeloma,

The market is analyzed on the basis of regions namely North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

The report divides the market into diverse segments such as types, applications, regions, end-users, technologies.CAR T-Cell Therapy for Multiple Myeloma market competitive scenario covers a study of participants core values, niche markets, missions, objectives, strengths, and weaknesses. The report mainly focuses on delivering competitive advantages to market players which will help them compete vigorously in the ever-changing business environment.

Furthermore, information related to current and future policies and regulations is organized in the report as well as the regulatory environment is an essential part of the CAR T-Cell Therapy for Multiple Myeloma market which needs special focus. The report presents substantial insights for forthcoming business opportunities, challenges, risks, obstacles, and restraints.Industry leading tools and techniques has been used to evaluate these market dynamics.

ACCESS FULL REPORT: https://www.fiormarkets.com/report/global-car-t-cell-therapy-for-multiple-myeloma-market-321825.html

Benefits of Purchasing This Report:

You will come to know a thorough CAR T-Cell Therapy for Multiple Myeloma analysis of the growth sector and able to design and improve your product development and sales strategies accordance to it. You can develop market-entry strategies to sustain competition as the competitors are performing out of the way through precise and updated strategies. You will be able to analyze business frameworks of the known players.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs.

Read this article:
Global CAR T-Cell Therapy for Multiple Myeloma Market 2019 Company Business Overview - Juno Therapeutics, Kite Pharma, Novartis, Collectis - Hitz...